Minerva Neurosciences, Inc. reported its third quarter 2025 financial results and business updates. The company announced it has secured $80 million in gross proceeds from a private placement completed on October 23, 2025, with the potential to receive up to an additional $120 million if certain warrants are exercised and clinical milestones are achieved. Minerva Neurosciences stated that, following recent financing and alignment with the FDA on a confirmatory Phase 3 clinical trial, it is advancing roluperidone for the treatment of negative symptoms of schizophrenia and preparing for a potential commercial launch in the US, if approved. For the quarter ended September 30, 2025, research and development (R&D) expenses were $0.9 million, down from $1.9 million in the same period in 2024. For the nine months ended September 30, 2025, R&D expenses totaled $3.6 million, compared to $9.9 million in the prior year period. The decrease in R&D expenses was attributed to lower costs related to the drug substance validation campaign, consultant fees, and compensation expenses.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568830-en) on November 05, 2025, and is solely responsible for the information contained therein.
Comments